Get the Stockscreener App
19.36
5.33%
0.98
After Hours:
19.36
Dyne Therapeutics Inc stock is traded at $19.36, with a volume of 2.00M.
It is up +5.33% in the last 24 hours and up +9.44% over the past month.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.
See More
Previous Close:
$18.38
Open:
$18.15
24h Volume:
2.00M
Relative Volume:
0.92
Market Cap:
$3.19B
Revenue:
-
Net Income/Loss:
$-446.21M
P/E Ratio:
-5.4637
EPS:
-3.5434
Net Cash Flow:
$-423.92M
1W Performance:
+2.76%
1M Performance:
+9.44%
6M Performance:
+31.88%
1Y Performance:
+156.42%
1-Day Range:
$18.14
$19.37
1-Week Range:
$17.81
$19.37
52-Week Range:
$6.71
$25.00
Dyne Therapeutics Inc Stock (DYN) Company Profile
Name
Dyne Therapeutics Inc
Sector
Industry
Phone
(781) 786-8230
Address
1560 TRAPELO ROAD, WALTHAM
Compare DYN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DYN
Dyne Therapeutics Inc
|
19.36 | 3.03B | 0 | -446.21M | -423.92M | -3.5434 |
VRTX
Vertex Pharmaceuticals Inc
|
446.78 | 112.92B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
767.85 | 81.99B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
800.50 | 48.82B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.28 | 43.66B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.42 | 34.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-10-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-10-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-25-25 | Upgrade | Raymond James | Outperform → Strong Buy |
| Jun-24-25 | Initiated | Bernstein | Mkt Perform |
| Jun-11-25 | Resumed | Raymond James | Outperform |
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| May-29-25 | Initiated | Evercore ISI | Outperform |
| Mar-12-25 | Initiated | BMO Capital Markets | Outperform |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Dec-13-24 | Initiated | Robert W. Baird | Outperform |
| Nov-26-24 | Initiated | RBC Capital Mkts | Outperform |
| Oct-24-24 | Downgrade | JP Morgan | Overweight → Neutral |
| May-21-24 | Reiterated | Chardan Capital Markets | Buy |
| Apr-30-24 | Initiated | Morgan Stanley | Overweight |
| Feb-20-24 | Initiated | H.C. Wainwright | Buy |
| Feb-27-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Feb-15-23 | Initiated | Oppenheimer | Outperform |
| Jan-26-23 | Initiated | Guggenheim | Buy |
| Jul-20-22 | Initiated | Chardan Capital Markets | Buy |
| Jul-12-22 | Initiated | Raymond James | Outperform |
| Oct-12-20 | Initiated | JP Morgan | Overweight |
| Oct-12-20 | Initiated | Jefferies | Buy |
| Oct-12-20 | Initiated | Piper Sandler | Overweight |
| Oct-12-20 | Initiated | Stifel | Buy |
View All
Dyne Therapeutics Inc Stock (DYN) Latest News
Fundamentals Check: Is Dyne Therapeutics Inc gaining market share2026 Dividend Review & Real-Time Buy Signal Notifications - baoquankhu1.vn
Precision Trading with Dyne Therapeutics Inc. (DYN) Risk Zones - Stock Traders Daily
Signal Recap: Is Dyne Therapeutics Inc gaining market shareGap Down & Daily Volume Surge Signals - baoquankhu1.vn
DYN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Will Dyne Therapeutics Inc benefit from green energy policiesMarket Activity Recap & Fast Gain Stock Tips - baoquankhu1.vn
DYN SEC FilingsDyne Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Targets Report: Is now the right time to enter Dyne Therapeutics Inc2026 Sector Review & Momentum Based Trading Ideas - baoquankhu1.vn
Aberdeen Group plc Purchases 551,412 Shares of Dyne Therapeutics, Inc. $DYN - MarketBeat
Tax-driven share sale by Dyne (DYN) CFO Lucera Erick disclosed - Stock Titan
What Dyne Therapeutics (DYN)'s ESOP Shelf Filing and Payer-Focused Launch Prep Means For Shareholders - Sahm
Dyne Therapeutics, Inc. (DYN) stock price, news, quote and history - Yahoo Finance UK
SG Americas Securities LLC Invests $5.19 Million in Dyne Therapeutics, Inc. $DYN - MarketBeat
Dyne Therapeutics Announces Participation at 2026 Academy of Managed Care Pharmacy (AMCP) Conference to Begin Shaping Access in US for Potential Neuromuscular Medicines - Sahm
Insider Buying: Brian Posner Acquires Additional Shares of Dyne Therapeutics Inc (DYN) - GuruFocus
Director at Dyne Therapeutics (DYN) adds 2,000 common shares - Stock Titan
[144] Dyne Therapeutics, Inc. SEC Filing - Stock Titan
Fed Watch: Can Dyne Therapeutics Inc disrupt its industryMarket Risk Analysis & Daily Volume Surge Trade Alerts - baoquankhu1.vn
DYN Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Technical Reactions to DYN Trends in Macro Strategies - Stock Traders Daily
Bullish analyst opinion on Dyne (DYNE) follows rare disease drug progress in Japan - MSN
Is Dyne Therapeutics Inc a turnaround storyPortfolio Performance Summary & Risk Adjusted Buy and Sell Alerts - baoquankhu1.vn
Biotech Price Target Raised on Strong FSHD & DM1 siRNA Data - Streetwise Reports
Clearbridge Small Cap Growth Strategy Added Dyne Therapeutics (DYN) in Q4 - Insider Monkey
Vanguard disaggregates holdings; Dyne Therapeutics (NASDAQ: DYN) shows 0 ownership - stocktitan.net
Rare Disease Biotech Sell Rating Maintained: Early Clinical Data Fails to Offset Flagship Drug Revenue Decline - Streetwise Reports
Raymond James reiterates Strong Buy on Dyne Therapeutics stock By Investing.com - Investing.com Canada
Dyne Therapeutics, Inc. (NASDAQ:DYN) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Dyne Therapeutics, Inc. $DYN Shares Bought by JPMorgan Chase & Co. - MarketBeat
Dyne Therapeutics (DYN) shares key details for pivotal drugs - MSN
MDA 2026: Dyne advances DMD therapy z-rostudirsen toward approval - Muscular Dystrophy News
Dyne Therapeutics (NASDAQ:DYN) Trading 4.4% HigherHere's Why - MarketBeat
Dyne Therapeutics Targets 2026 “Breakout Year” With DMD BLA Plans and DM1 Milestones at Stifel Conference - MarketBeat
Published on: 2026-03-19 20:58:12 - baoquankhu1.vn
Dyne Therapeutics details complex risk patterns and urgent care need for DM1 patients - Traders Union
Retail Trends: Is now the right time to enter Dyne Therapeutics IncOil Prices & Comprehensive Market Scan Insights - baoquankhu1.vn
Earnings Beat: Will Dyne Therapeutics Inc benefit from government policyWeekly Gains Report & Low Risk Profit Maximizing Plans - baoquankhu1.vn
Trading the Move, Not the Narrative: (DYN) Edition - Stock Traders Daily
Myotonic Dystrophy Pipeline 2026: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | Dyne Therapeutics, Avidity Biosciences, Harmony Biosciences, AMO Pharma - Barchart.com
MDA 2026: Dyne therapy boosts strength, cognition in DM1 - Muscular Dystrophy News
J.P. Morgan Reaffirms Their Hold Rating on Dyne Therapeutics (DYN) - The Globe and Mail
Is Dyne’s Phase 3 HARMONIA Launch Reframing The Investment Case For Dyne Therapeutics (DYN)? - simplywall.st
Why Dyne Therapeutics Stock Is Surging Higher Now - TipRanks
Braidwell LP Sells 542,868 Shares of Dyne Therapeutics, Inc. $DYN - MarketBeat
Dyne Therapeutics DMD And DM1 Progress Sharpens Rare Disease Investment Case - simplywall.st
Dyne Therapeutics Advances Rare Disease Pipeline With Pivotal Trials And Data - Yahoo Finance
Integral Health Asset Management LLC Buys New Position in Dyne Therapeutics, Inc. $DYN - MarketBeat
Dyne Therapeutics Insider Sold Shares Worth $2,530,562, According to a Recent SEC Filing - marketscreener.com
Director buys 2,000 Dyne Therapeutics (DYN) shares in open market - Stock Titan
Fund tied to Dyne Therapeutics (DYN) director sells stock - Stock Titan
Dyne Therapeutics (DYN) Shares Key Details For Pivotal. Drugs - Insider Monkey
WINTON GROUP Ltd Makes New Investment in Dyne Therapeutics, Inc. $DYN - MarketBeat
Dyne Therapeutics Inc Stock (DYN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.57%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):